Flezurafenib

Highest phase reached

Phase 2

Drug type

Small molecule

Listing at source: Listed

Highest phase reached: Phase 2
www.ebi.ac.uk

Drug type: Small molecule
www.ebi.ac.uk

Drug name: Flezurafenib
www.ebi.ac.uk

Molecular weight: 456.48
www.ebi.ac.uk

Structure (SMILES): O=C1CCc2c(Oc3ccc4c(c3)C[C@@H](c3ncc(-c5ccc(F)cc5)[nH]3)CO4)ccnc2N1
www.ebi.ac.uk

flezurafenib
Flezurafenib
flezurafenib [INN]
FLEZURAFENIB [USAN]
flezurafenib inn
flezurafenib usan
jzp 815
JZP-815
jzp815
JZP815

CAS registry numbers

2760321-00-2

ChEMBL ID: CHEMBL6068010
www.ebi.ac.uk

InChIKey: TWJSMWXWCWQPRO-QGZVFWFLSA-N
www.ebi.ac.uk

PubChem compound IDs

162772363

FDA ingredient codes (UNII)

P26TTM6U27

First in class: No
Orphan designation: No

Pharmacology name: flezurafenib
Type: Synthetic organic
Drug name stem: -rafenib

Investigated indications

Condition
Neoplasms
Highest recorded phase
2
Condition identifier
EFO:0000616
Subject identifier
D009369

Condition identifier
EFO_0000616
Condition identifier
MONDO_0005070

Hydrogen bond acceptors: 5
Hydrogen bond donors: 2
Polar surface area: 89.13
Calculated partition coefficient (ALogP): 5.01
Calculated partition coefficient (XLogP): 3.6
Prodrug: No
Chirality: Single enantiomer
Inorganic: No
Rule-of-five violations: 1
Rotatable bonds: 4
Heavy atoms: 34
Molecular formula: C26H21FN4O3
Monoisotopic mass: 456.15976871
Natural product: No

Related records

Trials (1)

A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815

In development for (1)

Neoplasm Phase 2